Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles
Open Access
- 28 April 2020
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 18 (1) , 1-18
Abstract
Nanoparticle based gene delivery systems holds great promise. Superparamagnetic iron oxide nanoparticles (SPIONs) are being heavily investigated due to good biocompatibility and added diagnostic potential, rendering such nanoparticles theranostic. Yet, commonly used cationic coatings for efficient delivery of such anionic cargos, results in significant toxicity limiting translation of the technology to the clinic. Here, we describe a highly biocompatible, small and non-cationic SPION-based theranostic nanoparticles as novel gene therapy agents. We propose for the first-time, the usage of the microRNA machinery RISC complex component Argonaute 2 (AGO2) protein as a microRNA stabilizing agent and a delivery vehicle. In this study, AGO2 protein-conjugated, anti-HER2 antibody-linked and fluorophore-tagged SPION nanoparticles were developed (SP-AH nanoparticles) and used as a carrier for an autophagy inhibitory microRNA, MIR376B. These functionalized nanoparticles selectively delivered an effective amount of the microRNA into HER2-positive breast cancer cell lines in vitro and in a xenograft nude mice model of breast cancer in vivo, and successfully blocked autophagy. Furthermore, combination of the chemotherapy agent cisplatin with MIR376B-loaded SP-AH nanoparticles increased the efficacy of the anti-cancer treatment both in vitro in cells and in vivo in the nude mice. Therefore, we propose that AGO2 protein conjugated SPIONs are a new class of theranostic nanoparticles and can be efficiently used as innovative, non-cationic, non-toxic gene therapy tools for targeted therapy of cancer.Keywords
Funding Information
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (213M669)
This publication has 50 references indexed in Scilit:
- Targeting autophagy during cancer therapy to improve clinical outcomesPharmacology & Therapeutics, 2011
- Characterization of extracellular circulating microRNANucleic Acids Research, 2011
- Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasmaProceedings of the National Academy of Sciences, 2011
- Phosphorylation of human Argonaute proteins affects small RNA bindingNucleic Acids Research, 2010
- Structural insights into RNA processing by the human RISC-loading complexNature Structural & Molecular Biology, 2009
- Expanded RNA-binding activities of mammalian Argonaute 2Nucleic Acids Research, 2009
- Binding and Cleavage Specificities of Human Argonaute2Journal of Biological Chemistry, 2009
- Silica nanoparticles as a delivery system for nucleic acid-based reagentsJournal of Materials Chemistry, 2009
- In vitro reconstitution of the human RISC-loading complexProceedings of the National Academy of Sciences, 2008
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003